Multiple Sclerosis (MS) Drug Market

FierceBiotech  7 hrs ago  Comment 
Novartis touts positive data from PhIII multiple sclerosis trial slawrence Thu, 08/25/2016 - 11:13  Aug 25  Comment 
NOVARTIS FINANCE S.A. / Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the...
TechCrunch  Aug 5  Comment 
 Toronto-based B corporation Komodo OpenLab thought Pokémon Go using its Tecla product, an assistive hardware device designed to make it easier to use smartphones, tablets and users for people who might not generally be able to interact with...
Motley Fool  Jul 26  Comment 
The market for multiple sclerosis drugs is worth billions of dollars every year and these are the companies that benefit most.
Benzinga  Jul 5  Comment 
Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) disclosed Tuesday that the European Commission (EC) has granted marketing authorization for its ZINBRYTA (daclizumab) for the treatment of adult patients suffering from relapsing forms of multiple...
MedPage Today  Jun 28  Comment 
(MedPage Today) -- Genetically determined change in weight tied to increased risk of multiple sclerosis
FierceBiotech  Jun 28  Comment 
Roche’s new multiple sclerosis drug set for early FDA approval badams Tue, 06/28/2016 - 05:52  Jun 13  Comment 
PARIS (dpa-AFX) - German drug maker Merck KGaA (MKGAY.PK) announced Monday that it has entered into an agreement with HAPPYneuron, a subsidiary of SBT Group of France, in which Merck will receive an exclusive license to the company's...
GenEng News  Jun 2  Comment 
Researchers at the University of British Columbia have discovered a rare genetic mutation that causes multiple sclerosis, which should erase doubts that some forms of the neurological disease are inherited.  


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki